

# Ruth KnÃ¼chel-Clarke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4783406/publications.pdf>

Version: 2024-02-01

62  
papers

2,177  
citations

304743

22  
h-index

243625

44  
g-index

65  
all docs

65  
docs citations

65  
times ranked

4112  
citing authors

#	ARTICLE	IF	CITATIONS
1	Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. <i>Advanced Drug Delivery Reviews</i> , 2019, 138, 302-325.	13.7	731
2	Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. <i>Nature Medicine</i> , 2016, 22, 288-297.	30.7	191
3	Iron metabolism: pathophysiology and pharmacology. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 640-656.	8.7	87
4	Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR. <i>Oncotarget</i> , 2017, 8, 86253-86263.	1.8	64
5	Virtual CT autopsy in clinical pathology: feasibility in clinical autopsies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 211-219.	2.8	63
6	Multisystemic Cellular Tropism of SARS-CoV-2 in Autopsies of COVID-19 Patients. <i>Cells</i> , 2021, 10, 1900.	4.1	50
7	Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 599-608.	2.8	45
8	Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS. <i>BioMed Research International</i> , 2015, 2015, 1-23.	1.9	44
9	Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas. <i>International Journal of Cancer</i> , 2018, 143, 1764-1773.	5.1	44
10	Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 749-758.	2.8	43
11	Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1078-1087.	1.6	42
12	Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours. <i>Carcinogenesis</i> , 2014, 35, 727-736.	2.8	38
13	Interference with ERK-dimerization at the nucleocytoplasmic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects. <i>Nature Communications</i> , 2020, 11, 1733.	12.8	38
14	An engineered multicomponent bone marrow niche for the recapitulation of hematopoiesis at ectopic transplantation sites. <i>Journal of Hematology and Oncology</i> , 2016, 9, 4.	17.0	35
15	First report from the German COVID-19 autopsy registry. <i>Lancet Regional Health - Europe</i> , 2022, 15, 100330.	5.6	33
16	Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer. <i>Clinical Epigenetics</i> , 2018, 10, 15.	4.1	32
17	Proteomic profiling in Lipocalin 2 deficient mice under normal and inflammatory conditions. <i>Journal of Proteomics</i> , 2013, 78, 188-196.	2.4	30
18	Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome. <i>Epigenetics</i> , 2015, 10, 903-912.	2.7	30

#	ARTICLE	IF	CITATIONS
19	Epigenetic inactivation of the novel candidate tumor suppressor gene <i>ITIH5</i> in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype. <i>Epigenetics</i> , 2014, 9, 1290-1301.	2.7	29
20	Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms. <i>Journal of Hematology and Oncology</i> , 2014, 7, 92.	17.0	29
21	<i>ITIH5</i> mediates epigenetic reprogramming of breast cancer cells. <i>Molecular Cancer</i> , 2017, 16, 44.	19.2	29
22	Contrast-enhanced postmortem computed tomography in clinical pathology: enhanced value of 20 clinical autopsies. <i>Human Pathology</i> , 2014, 45, 1813-1823.	2.0	26
23	<i>ARID1A</i> -deficiency in urothelial bladder cancer: No predictive biomarker for <i>EZH2</i> -inhibitor treatment response?. <i>PLoS ONE</i> , 2018, 13, e0202965.	2.5	25
24	Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. <i>BMC Cancer</i> , 2020, 20, 230.	2.6	24
25	Contrast-enhanced CT imaging in patients with chronic kidney disease. <i>Angiogenesis</i> , 2016, 19, 525-535.	7.2	22
26	Interactions Between Bladder Tumor Cells as Tumor Spheroids from the Cell Line J82 and Human Endothelial Cells in Vitro. <i>Journal of Urology</i> , 1988, 139, 640-645.	0.4	21
27	<i>ITIH5</i> induces a shift in <i>TGF<math>\beta</math></i> superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death. <i>Molecular Carcinogenesis</i> , 2018, 57, 167-181.	2.7	21
28	Interleukin-17A is overexpressed in inflammatory skin diseases and affects epidermal morphology in constitutive knockout mice and murine 3D skin models. <i>Experimental Dermatology</i> , 2015, 24, 663-668.	2.9	20
29	Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. <i>American Journal of Pathology</i> , 2020, 190, 323-332.	3.8	20
30	Autopsy registry can facilitate COVID-19 research. <i>EMBO Molecular Medicine</i> , 2020, 12, e12885.	6.9	20
31	SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. <i>Oncotarget</i> , 2019, 10, 6494-6508.	1.8	19
32	Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 4409.	3.7	18
33	<i>ITIH5</i> and <i>ECRG4</i> DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1117.	4.1	18
34	Risk and timing of biochemical recurrence in pT3aN0/Nx prostate cancer with positive surgical margin – A multicenter study. <i>Radiotherapy and Oncology</i> , 2015, 116, 119-124.	0.6	16
35	Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11547.	4.1	16
36	The Use of Contrast-Enhanced Post Mortem CT in the Detection of Cardiovascular Deaths. <i>PLoS ONE</i> , 2014, 9, e93101.	2.5	15

#	ARTICLE	IF	CITATIONS
37	Optical Tomography of MMP Activity Allows a Sensitive Noninvasive Characterization of the Invasiveness and Angiogenesis of SCC Xenografts. <i>Neoplasia</i> , 2014, 16, 235-246.e1.	5.3	12
38	Bladder Cancer Stage Development, 2004-2014 in Europe Compared With the United States: Analysis of European Population-based Cancer Registries, the United States SEER Database, and a Large Tertiary Institutional Cohort. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 162-170.e4.	1.9	12
39	Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 807-819.	4.4	12
40	Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection. <i>Cancers</i> , 2020, 12, 3826.	3.7	11
41	Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 325-335.	2.8	11
42	The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells. <i>Cells</i> , 2021, 10, 1038.	4.1	11
43	SARS-CoV-2 RNA screening in routine pathology specimens. <i>Microbial Biotechnology</i> , 2021, 14, 1627-1641.	4.2	9
44	MSI testing. <i>Der Pathologe</i> , 2021, 42, 110-118.	1.6	9
45	Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e629-e642.	1.9	8
46	Gleason Score 6 - Prostate Cancer or Benign Variant?. <i>Oncology Research and Treatment</i> , 2015, 38, 629-632.	1.2	7
47	Risk of biochemical recurrence and timing of radiotherapy in pT3a prostate cancer with positive surgical margin. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 440-448.	2.0	6
48	Molecular Characterization of Muellierian Tumors of the Urinary Tract. <i>Genes</i> , 2021, 12, 880.	2.4	5
49	Cooperative approach of pathology and neuropathology in the COVID-19 pandemic. <i>Der Pathologe</i> , 2021, 42, 69-75.	1.6	4
50	An unusual case of aortic metastasis from lung cancer. <i>Discoveries</i> , 2020, 8, e106.	2.3	4
51	ITIH5-Derived Polypeptides Covering the VIT Domain Suppress the Growth of Human Cancer Cells In Vitro. <i>Cancers</i> , 2022, 14, 488.	3.7	4
52	The impact of complete embedding of remaining tissue in gynecological lymph node dissection specimen in surgical pathology on lymph node yield: is it clinically relevant?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 183-188.	2.8	3
53	SWI/SNF Alterations in Squamous Bladder Cancers. <i>Genes</i> , 2020, 11, 1368.	2.4	3
54	The Impact of Fluorescence in situ Hybridization on the Staging of Upper Tract Urothelial Carcinoma. <i>Urologia Internationalis</i> , 2021, 105, 631-636.	1.3	3

#	ARTICLE	IF	CITATIONS
55	Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 83-92.	2.8	3
56	Effective Radiosensitization of Bladder Cancer Cells by Pharmacological Inhibition of DNA-PK and ATR. Biomedicines, 2022, 10, 1277.	3.2	3
57	Towards sustainable data management in professional biobanking. Studies in Health Technology and Informatics, 2015, 212, 94-102.	0.3	2
58	&lt;i>In vivo&/i> quantification of amyloid burden in TTR-related cardiac amyloidosis. Intractable and Rare Diseases Research, 2017, 6, 291-294.	0.9	1
59	Development of a Rapid Analysis Method for Bone Resection Margins for Oral Squamous Cell Carcinoma by Immunoblotting. Head and Neck Pathology, 2018, 12, 210-220.	2.6	1
60	Response letter to "What can be more prognostic than the pTNM category assessed in radical cystectomy samples?" by S&#228;4&#228;sd F, Ivanyi B and Pajor L. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 483-484.	2.8	0
61	Editorial for: Bertoni et al. ex vivo fluorescence confocal microscopy: prostatic and periprostatic tissues atlas and evaluation of the learning curve. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 487-488.	2.8	0
62	Genetic instability after radiotherapy in prostate cancer: TMRSS2-ERG fusion in salvage radical prostatectomies.. Journal of Clinical Oncology, 2013, 31, 182-182.	1.6	0